{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:05:57Z","timestamp":1777950357558,"version":"3.51.4"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004447","name":"Japan Foundation New York","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016571","name":"Institute of Natural Medicine, University of Toyama","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016571","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020051","name":"Tamura Science and Technology Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020051","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17H06398"],"award-info":[{"award-number":["17H06398"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K22801"],"award-info":[{"award-number":["20K22801"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21H02640"],"award-info":[{"award-number":["21H02640"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K15311"],"award-info":[{"award-number":["21K15311"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.biopha.2023.115241","type":"journal-article","created":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T04:59:25Z","timestamp":1690606765000},"page":"115241","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Drug-induced altered self-presentation increases tumor immunogenicity"],"prefix":"10.1016","volume":"165","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1512-0753","authenticated-orcid":false,"given":"Takeshi","family":"Susukida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9092-7181","authenticated-orcid":false,"given":"So-ichiro","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Shirayanagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2821-0651","authenticated-orcid":false,"given":"Shigeki","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kousei","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7921-1171","authenticated-orcid":false,"given":"Yoshihiro","family":"Hayakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.biopha.2023.115241_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/antib9040065","article-title":"Discovery strategies to maximize the clinical potential of t-cell engaging antibodies for the treatment of solid tumors","volume":"9","author":"Voynov","year":"2020","journal-title":"Antibodies"},{"issue":"3","key":"10.1016\/j.biopha.2023.115241_bib2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41585-020-0282-3","article-title":"Checkpoint inhibitor immunotherapy in kidney cancer","volume":"17","author":"Xu","year":"2020","journal-title":"Nat. Rev. Urol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115241_bib3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/annonc\/mdx686","article-title":"Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy","volume":"29","author":"Rotte","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2023.115241_bib4","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.semcancer.2020.01.001","article-title":"Exposing hidden targets: combining epigenetic and immunotherapy to overcome cancer resistance","volume":"65","author":"Olino","year":"2020","journal-title":"Semin Cancer Biol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115241_bib5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s40425-018-0479-7","article-title":"High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors","volume":"6","author":"Maleki Vareki","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"11","key":"10.1016\/j.biopha.2023.115241_bib6","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.biopha.2023.115241_bib7","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2023.115241_bib8","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s00251-017-1007-5","article-title":"The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions","volume":"69","author":"Illing","year":"2017","journal-title":"Immunogenetics"},{"issue":"1","key":"10.1016\/j.biopha.2023.115241_bib9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.dmpk.2016.11.003","article-title":"Human leukocyte antigen and idiosyncratic adverse drug reactions","volume":"32","author":"Usui","year":"2017","journal-title":"Drug Metab. Pharm."},{"issue":"6","key":"10.1016\/j.biopha.2023.115241_bib10","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.immuni.2008.04.020","article-title":"Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity","volume":"28","author":"Chessman","year":"2008","journal-title":"Immunity"},{"issue":"7404","key":"10.1016\/j.biopha.2023.115241_bib11","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nature11147","article-title":"Immune self-reactivity triggered by drug-modified HLA-peptide repertoire","volume":"486","author":"Illing","year":"2012","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.biopha.2023.115241_bib12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.coi.2012.10.002","article-title":"Human leukocyte antigen-associated drug hypersensitivity","volume":"25","author":"Illing","year":"2013","journal-title":"Curr. Opin. Immunol."},{"issue":"10","key":"10.1016\/j.biopha.2023.115241_bib13","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.2217\/14622416.9.10.1531","article-title":"Current trends in screening across ethnicities for hypersensitivity to abacavir","volume":"9","author":"Rodriguez-Novoa","year":"2008","journal-title":"Pharmacogenomics"},{"issue":"4","key":"10.1016\/j.biopha.2023.115241_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095339","article-title":"Abacavir induced T cell reactivity from drug naive individuals shares features of allo-immune responses","volume":"9","author":"Adam","year":"2014","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.biopha.2023.115241_bib15","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1172\/JCI99321","article-title":"A transgenic mouse model for HLA-B*57:01-linked abacavir drug tolerance and reactivity","volume":"128","author":"Cardone","year":"2018","journal-title":"J. Clin. Investig."},{"issue":"5","key":"10.1016\/j.biopha.2023.115241_bib16","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1021\/tx400060p","article-title":"T-cells from HLA-B*57:01+ human subjects are activated with abacavir through two independent pathways and induce cell death by multiple mechanisms","volume":"26","author":"Bell","year":"2013","journal-title":"Chem. Res. Toxicol."},{"issue":"3","key":"10.1016\/j.biopha.2023.115241_bib17","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00204-017-2112-9","article-title":"Evaluation of immune-mediated idiosyncratic drug toxicity using chimeric HLA transgenic mice","volume":"92","author":"Susukida","year":"2018","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.biopha.2023.115241_bib18","unstructured":"National Research Council. Guide for the Care and Use of Laboratory Animals, 8th Edition, Washington DC, 2011."},{"issue":"6","key":"10.1016\/j.biopha.2023.115241_bib19","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1248\/bpb.b20-00102","article-title":"Detection of Abacavir-Induced Structural Alterations in Human Leukocyte Antigen-B*57: 01 Using Phage Display","volume":"43","author":"Shirayanagi","year":"2020","journal-title":"Biol. Pharm. Bull."},{"issue":"6","key":"10.1016\/j.biopha.2023.115241_bib20","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/laban.254","article-title":"Estimation of rat mammary tumor volume using caliper and ultrasonography measurements","volume":"42","author":"Faustino-Rocha","year":"2013","journal-title":"Lab Anim."},{"issue":"1","key":"10.1016\/j.biopha.2023.115241_bib21","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/s42003-021-02657-2","article-title":"Regulation of the immune tolerance system determines the susceptibility to HLA-mediated abacavir-induced skin toxicity","volume":"4","author":"Susukida","year":"2021","journal-title":"Commun. Biol."},{"issue":"9","key":"10.1016\/j.biopha.2023.115241_bib22","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1111\/cas.15050","article-title":"NKG2D defines tumor-reacting effector CD8(+) T cells within tumor microenvironment","volume":"112","author":"Mojic","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.biopha.2023.115241_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioelechem.2021.107831","article-title":"Mutational burden, MHC-I expression and immune infiltration as limiting factors for in situ vaccination by TNFalpha and IL-12 gene electrotransfer","volume":"140","author":"Kamensek","year":"2021","journal-title":"Bioelectrochemistry"},{"issue":"6","key":"10.1016\/j.biopha.2023.115241_bib24","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1259049","article-title":"Modulation of MHC class I surface expression in B16F10 melanoma cells by methylseleninic acid","volume":"6","author":"Lennicke","year":"2017","journal-title":"Oncoimmunology"},{"issue":"12","key":"10.1016\/j.biopha.2023.115241_bib25","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1480301","article-title":"An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer","volume":"7","author":"Liede","year":"2018","journal-title":"Oncoimmunology"},{"issue":"9","key":"10.1016\/j.biopha.2023.115241_bib26","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nri.2017.49","article-title":"Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy","volume":"17","author":"Nagarsheth","year":"2017","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2023.115241_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000999","article-title":"A heat-shocked melanoma cell lysate vaccine enhances tumor infiltration by prototypic effector T cells inhibiting tumor growth","volume":"8","author":"Gleisner","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2023.115241_bib28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.coi.2016.05.003","article-title":"Allotype specific interactions of drugs and HLA molecules in hypersensitivity reactions","volume":"42","author":"Illing","year":"2016","journal-title":"Curr. Opin. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2023.115241_bib29","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1158\/1078-0432.CCR-14-3175","article-title":"Cancer neoantigens and applications for immunotherapy","volume":"22","author":"Desrichard","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2023.115241_bib30","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12943-019-1055-6","article-title":"Neoantigen vaccine: an emerging tumor immunotherapy","volume":"18","author":"Peng","year":"2019","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2023.115241_bib31","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41467-017-02630-w","article-title":"DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer","volume":"9","author":"Luo","year":"2018","journal-title":"Nat. Commun."},{"issue":"7806","key":"10.1016\/j.biopha.2023.115241_bib32","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41586-020-2229-5","article-title":"Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I","volume":"581","author":"Yamamoto","year":"2020","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.biopha.2023.115241_bib33","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1053\/gast.2000.18157","article-title":"Mouse alpha-fetoprotein-specific DNA-based immunotherapy of hepatocellular carcinoma leads to tumor regression in mice","volume":"119","author":"Grimm","year":"2000","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.biopha.2023.115241_bib34","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1158\/2326-6066.CIR-16-0114","article-title":"Rational selection of syngeneic preclinical tumor models for immunotherapeutic drug discovery","volume":"5","author":"Mosely","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"5","key":"10.1016\/j.biopha.2023.115241_bib35","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.jaci.2019.09.013","article-title":"Single-cell transcriptomics reveal polyclonal memory T-cell responses in skin with positive abacavir patch test results","volume":"144","author":"Redwood","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115241_bib36","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1364828","article-title":"PD-1 expression on tumor-specific T cells: friend or foe for immunotherapy","volume":"7","author":"Simon","year":"2017","journal-title":"Oncoimmunology"},{"issue":"3","key":"10.1016\/j.biopha.2023.115241_bib37","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00281-019-00734-7","article-title":"A new therapeutic target: the CD69-Myl9 system in immune responses","volume":"41","author":"Kimura","year":"2019","journal-title":"Semin Immunopathol."},{"issue":"12","key":"10.1016\/j.biopha.2023.115241_bib38","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2023.115241_bib39","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat. Immunol."},{"issue":"7","key":"10.1016\/j.biopha.2023.115241_bib40","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1086\/529382","article-title":"A. Study of Hypersensitivity to, T. Pharmacogenetic Evaluation Study, High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients","volume":"46","author":"Saag","year":"2008","journal-title":"Clin. Infect. Dis."},{"issue":"10","key":"10.1016\/j.biopha.2023.115241_bib41","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0149-2918(02)80057-1","article-title":"The abacavir hypersensitivity reaction: a review","volume":"24","author":"Clay","year":"2002","journal-title":"Clin. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2023.115241_bib42","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00432-018-2819-x","article-title":"Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma","volume":"145","author":"Indini","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2023.115241_bib43","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1080\/03602532.2020.1800725","article-title":"HLA transgenic mice: application in reproducing idiosyncratic drug toxicity","volume":"52","author":"Susukida","year":"2020","journal-title":"Drug Metab. Rev."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223010326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223010326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:03:48Z","timestamp":1777878228000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223010326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":43,"alternative-id":["S0753332223010326"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115241","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-induced altered self-presentation increases tumor immunogenicity","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115241","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"115241"}}